Segment 7 - Diagnosis Among Different Patient Populations

The panelists discuss how diagnosis and treatment of multiple myeloma might vary within different patient populations. They also analyze the costs associated with care for the disease within different populations.

Dr Kumar questions the ROI for different treatments, as well as for the side effects associated with their administration. He says it’s important to identify those patients who will benefit the most from the most expensive emerging agents.

Ms Young agrees, suggesting that treatment should be personalized to each specific patients’ needs. Managing toxicities may also result in cost savings. Ms Young further suggests that clinical trials hold potential that is beneficial for determining cost-effective treatment plans in targeted patient groups.